A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome-Reference-Cited by-同舟云学术

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

Published:2018-10 Issue:10 Volume:18 Page:658-663.e2
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Yalniz Fevzi Firat,Daver Naval,Rezvani Katayoun,Kornblau Steven,Ohanian Maro,Borthakur Gautam,DiNardo Courtney D.,Konopleva Marina,Burger Jan,Gasior Yvonne,Pierce Sherry,Kantarjian Hagop,Garcia-Manero Guillermo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management;Garcia-Manero;Am J Hematol,2014

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis;Koreth;J Clin Oncol,2013

4. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation;Oran;Biol Blood Marrow Transplant,2014

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies;Experimental Hematology & Oncology;2024-02-23

2. Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers;Pharmaceutics;2023-07-21

3. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment;International Journal of Molecular Sciences;2023-07-19

4. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease;OncoImmunology;2023-01-07

5. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond;International Journal of Molecular Sciences;2022-12-22